Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9

被引：61

作者：

Afolabi, Lukman O. ^{[1
,2
,3
]}

Adeshakin, Adeleye O. ^{[1
,2
]}

Sani, Musbahu M. ^{[3
]}

Bi, Jiacheng ^{[1
]}

Wan, Xiaochun ^{[1
,2
]}

机构：

[1] Chinese Acad Sci, Shenzhen Lab Antibody Engn, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, 1068 Xueyuan Ave, Shenzhen, Peoples R China

[2] Univ Chinese Acad Sci, Beijing, Peoples R China

[3] Fed Univ Dutse, Fac Sci, Dept Biochem, Dutse, Jigawa State, Nigeria

来源：

IMMUNOLOGY | 2019年 / 158卷 / 02期

关键词：

checkpoint; delivery; genetic manipulation; NK dysfunction; off-target; NATURAL-KILLER-CELLS; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; ANTITUMOR-ACTIVITY; PROGNOSTIC-SIGNIFICANCE; CAS9; RIBONUCLEOPROTEIN; IN-VITRO; INFILTRATION; ACTIVATION; ENHANCE;

D O I：

10.1111/imm.13094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Natural killer cells are potent cytotoxic lymphocytes specialized in recognizing and eliminating transformed cells, and in orchestrating adaptive anti-tumour immunity. However, NK cells are usually functionally exhausted in the tumour microenvironment. Strategies such as checkpoint blockades are under investigation to overcome NK cell exhaustion in order to boost anti-tumour immunity. The discovery and development of the CRISPR/Cas9 technology offer a flexible and efficient gene-editing capability in modulating various pathways that mediate NK cell exhaustion, and in arming NK cells with novel chimeric antigen receptors to specifically target tumour cells. Despite the high efficiency in its gene-editing capability, difficulty in the delivery of the CRISPR/Cas9 system remains a major bottleneck for its therapeutic applications, particularly for NK cells. The current review discusses feasible approaches to deliver the CRISPR/Cas9 systems, as well as potential strategies in gene-editing for NK cell immunotherapy for cancers.

引用

页码：63 / 69

页数：7

共 68 条

[1]

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor [J].

Adachi, Keishi ;

Kano, Yosuke ;

Nagai, Tomohiko ;

Okuyama, Namiko ;

Sakoda, Yukimi ;

Tamada, Koji .

NATURE BIOTECHNOLOGY, 2018, 36 (04) :346-+

[2]

In vivo CRISPR editing with no detectable genome-wide off-target mutations [J].

Akcakaya, Pinar ;

Bobbin, Maggie L. ;

Guo, Jimmy A. ;

Malagon-Lopez, Jose ;

Clement, Kendell ;

Garcia, Sara P. ;

Fellows, Mick D. ;

Porritt, Michelle J. ;

Firth, Mike A. ;

Carreras, Alba ;

Baccega, Tania ;

Seeliger, Frank ;

Bjursell, Mikael ;

Tsai, Shengdar Q. ;

Nguyen, Nhu T. ;

Nitsch, Roberto ;

Mayr, Lorenz M. ;

Pinello, Luca ;

Bohlool-Y, Mohammad ;

Aryee, Martin J. ;

Maresca, Marcello ;

Joung, J. Keith .

NATURE, 2018, 561 (7723) :416-+

[3]

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells [J].

Altvater, Bianca ;

Landmeier, Silke ;

Pscherer, Sibylle ;

Temme, Jaane ;

Schweer, Katharina ;

Kailayangiri, Sareetha ;

Campana, Dario ;

Juergens, Heribert ;

Pule, Martin ;

Rossig, Claudia .

CLINICAL CANCER RESEARCH, 2009, 15 (15) :4857-4866

[4]

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[5]

CRISPR provides acquired resistance against viruses in prokaryotes [J].

Barrangou, Rodolphe ;

Fremaux, Christophe ;

Deveau, Helene ;

Richards, Melissa ;

Boyaval, Patrick ;

Moineau, Sylvain ;

Romero, Dennis A. ;

Horvath, Philippe .

SCIENCE, 2007, 315 (5819) :1709-1712

[6]

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy [J].

Beavis, Paul A. ;

Henderson, Melissa A. ;

Giuffrida, Lauren ;

Mills, Jane K. ;

Sek, Kevin ;

Cross, Ryan S. ;

Davenport, Alexander J. ;

John, Liza B. ;

Mardiana, Sherly ;

Slaney, Clare Y. ;

Johnstone, Ricky W. ;

Trapani, Joseph A. ;

Stagg, John ;

Loi, Sherene ;

Kats, Lev ;

Gyorki, David ;

Kershaw, Michael H. ;

Darcy, Phillip K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (03) :929-941

[7]

NK Cell exhaustion [J].

Bi, Jiacheng ;

Tian, Zhigang .

FRONTIERS IN IMMUNOLOGY, 2017, 8

[8]

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy [J].

Blake, Stephen J. ;

Stannard, Kimberley ;

Liu, Jing ;

Allen, Stacey ;

Yong, Michelle C. R. ;

Mittal, Deepak ;

Aguilera, Amelia Roman ;

Miles, John J. ;

Lutzky, Viviana P. ;

de Andrade, Lucas Ferrari ;

Martinet, Ludovic ;

Colonna, Marco ;

Takeda, Kazuyoshi ;

Kuehnel, Florian ;

Gurlevik, Engin ;

Bernhardt, Guenter ;

Teng, Michele W. L. ;

Smyth, Mark J. .

CANCER DISCOVERY, 2016, 6 (04) :446-459

[9]

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19 [J].

Carlsten, Mattias ;

Levy, Emily ;

Karambelkar, Amrita ;

Li, Linhong ;

Reger, Robert ;

Berg, Maria ;

Peshwa, Madhusudan V. ;

Childs, Richard W. .

FRONTIERS IN IMMUNOLOGY, 2016, 7

[10]

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes [J].

Caruana, Ignazio ;

Savoldo, Barbara ;

Hoyos, Valentina ;

Weber, Gerrit ;

Liu, Hao ;

Kim, Eugene S. ;

Ittmann, Michael M. ;

Marchetti, Dario ;

Dotti, Gianpietro .

NATURE MEDICINE, 2015, 21 (05) :524-U158

← 1 2 3 4 5 6 7 →